Published in Oncogene on June 18, 1998
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res (2005) 1.11
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
Resistance of mitochondrial p53 to dominant inhibition. Mol Cancer (2008) 1.01
Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer (2012) 0.99
Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci (2014) 0.98
Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol (2006) 0.96
Role of p53 in Cell Death and Human Cancers. Cancers (Basel) (2011) 0.95
Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun (2012) 0.89
Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest (2001) 0.88
Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. Mol Cell Biol (2003) 0.85
Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget (2016) 0.85
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys (2011) 0.84
Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53. J Biol Chem (2012) 0.79
Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway. J Biol Chem (2015) 0.77
Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. Mol Oncol (2017) 0.75
Mutant p53 and ETS2, a Tale of Reciprocity. Front Oncol (2016) 0.75
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication. J Clin Invest (2017) 0.75
Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. PLoS One (2015) 0.75
Functional interactions of the simian virus 40 core origin of replication with flanking regulatory sequences. J Virol (1986) 3.15
Domain structure of the simian virus 40 core origin of replication. Mol Cell Biol (1986) 2.72
The adenine-thymine domain of the simian virus 40 core origin directs DNA bending and coordinately regulates DNA replication. Mol Cell Biol (1986) 2.31
The T-antigen-binding domain of the simian virus 40 core origin of replication. J Virol (1987) 2.08
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene (2011) 1.95
Simian virus 40 large tumor antigen requires three core replication origin domains for DNA unwinding and replication in vitro. Proc Natl Acad Sci U S A (1987) 1.89
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
p53 binds to the TATA-binding protein-TATA complex. J Biol Chem (1993) 1.42
Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene (2007) 1.41
Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol (1996) 1.37
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med (1985) 1.26
Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation (1997) 1.20
Optimization of benzoyl peroxide concentration in an experimental bone cement based on poly(methyl methacrylate). J Mater Sci Mater Med (1997) 1.19
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol (1997) 1.17
Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene (1994) 1.16
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol (1998) 1.14
Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene (2000) 1.14
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene (2006) 1.11
Isolation of an amino-terminal region of bovine papillomavirus type 1 E1 protein that retains origin binding and E2 interaction capacity. J Virol (1997) 1.11
Analysis of the herpes simplex virus type 1 OriS sequence: mapping of functional domains. J Virol (1991) 1.10
The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol (1993) 1.09
N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene (1995) 1.08
The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene (2012) 1.06
Dermatology referrals in the hospital setting. Indian J Dermatol Venereol Leprol (2007) 1.06
Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. Eur J Neurosci (1998) 1.05
Profile of behavioural risk factors of non-communicable diseases in an urban setting in New Delhi. Indian J Public Health (2009) 1.04
Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene (2007) 1.04
Pregnancy and the prolactin family of hormones: coordination of anterior pituitary, uterine, and placental expression. Endocr Rev (1991) 1.01
Ascorbic acid metabolism in diabetes mellitus. Metabolism (1981) 1.00
Ontogeny of placental lactogen-I and placental lactogen-II expression in the developing rat placenta. Dev Biol (1990) 0.99
Novel hydroxyapatite-based dental composites. Biomaterials (1994) 0.98
Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol (1995) 0.97
Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene (1994) 0.97
Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol (1994) 0.93
Analysis of the DNA-binding domain of the HSV-1 origin-binding protein. Virology (1994) 0.92
Automated follicle tracking improves measurement reliability in patients undergoing ovarian stimulation. Reprod Biomed Online (2009) 0.92
Granuloma formation in Schistosoma japonicum infected nude mice: the effects of reconstitution with L3T4+ or Lyt2+ splenic cells. Am J Trop Med Hyg (1989) 0.90
Genotoxic effect of arecoline given either by the peritoneal or oral route in murine bone marrow cells and the influence of N-acetylcysteine. Cancer Lett (1999) 0.90
Traumatic pseudomeningocele at cranio-vertebral junction following stab injury. Injury (1998) 0.90
p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein. Biochem Biophys Res Commun (1993) 0.89
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ (2012) 0.89
Dehydroascorbic acid reduction in human erythrocytes. Biochem Biophys Res Commun (1979) 0.88
Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin. Endocrinology (2000) 0.87
Diffuse neurofibroma of scalp. Neurol India (2002) 0.86
Bioresorbable glass fibres facilitate peripheral nerve regeneration. J Hand Surg Br (2005) 0.86
Primary anaplastic pilocytic astrocytoma. J Clin Neurosci (2009) 0.86
Differential expression of the estrogen receptors alpha and beta in the rat corpus luteum of pregnancy: regulation by prolactin and placental lactogens. Endocrinology (1998) 0.85
Differential expression of placental lactogen-II and prolactin-like protein-A in the rat chorioallantoic placenta. Endocrinology (1989) 0.85
Cloning and expression of an equine herpesvirus 1 origin-binding protein. J Virol (1994) 0.83
Generation and characterization of antipeptide antibodies to rat cytochrome P-450 side-chain cleavage enzyme. Mol Cell Endocrinol (1991) 0.83
Persistence of eggs and hepatic fibrosis after treatment of Schistosoma mansoni-infected mice. Am J Trop Med Hyg (1992) 0.82
Early up-regulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in rats with hemorrhagic shock and resuscitation. Shock (1999) 0.82
Effect of triphenyl bismuth on glass transition temperature and residual monomer content of acrylic bone cements. J Biomater Sci Polym Ed (2003) 0.81
Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res (2014) 0.81
Spontaneous differentiation of trophoblast cells along the spongiotrophoblast cell pathway: expression of members of the placental prolactin gene family and modulation by retinoic acid. Dev Biol (1994) 0.81
Poly(acrylic acid) modified calcium phosphate cements: the effect of the composition of the cement powder and of the molecular weight and concentration of the polymeric acid. J Mater Sci Mater Med (2007) 0.81
A fatal case of ischaemic colitis following long-term use of neuroleptic medication. J Intellect Disabil Res (1992) 0.81
Effect of cross-linking agents on the dynamic mechanical properties of hydrogel blends of poly(acrylic acid)-poly(vinyl alcohol-vinyl acetate). Biomaterials (1996) 0.81
Effects of exercise and of food restriction on the development of spontaneous obesity in rats. J Nutr (1975) 0.81
Human oncoprotein mdm2 interacts with the tata-binding protein in-vitro and in-vivo. Int J Oncol (1995) 0.81
Decidual prolactin-related protein. Identification, molecular cloning, and characterization. J Biol Chem (1993) 0.81
p73 transcriptional activity increases upon cooperation between its spliced forms. Oncogene (2000) 0.80
Isodense acute subdural haematoma in anaemic patients. Neurol India (2000) 0.80
Regional and age-related expression of gelatinases in the brains of young and old rats after treatment with kainic acid. Neurosci Lett (2000) 0.80
Three-dimensional ultrasonographic characteristics of endometriomata. Ultrasound Obstet Gynecol (2008) 0.80
Are opioid antagonists effective in reducing self-injury in adults with intellectual disability? A systematic review. J Intellect Disabil Res (2014) 0.79
Natural history of Schistosoma mansoni infection in mice: egg production, egg passage in the feces, and contribution of host and parasite death to changes in worm numbers. Am J Trop Med Hyg (1994) 0.79
Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. J Intellect Disabil Res (2009) 0.79
Cell-type-specific induction of the UL9 gene of HSV-1 by cell signaling pathway. Biochem Biophys Res Commun (1994) 0.79
Disruption of functions of wild-type p53 by hetero-oligomerization. Int J Oncol (1999) 0.79
Specialist training in obstetrics and gynaecology: a survey on work-life balance and stress among trainees in UK. J Obstet Gynaecol (2006) 0.79
Maintenance requirement and energetic efficiency of lean and obese Zucker rats. J Nutr (1976) 0.79
Differential modulation of cellular and viral promoters by p73 and p53. Int J Oncol (2001) 0.79
Analysis of the promoter sequences of the UL9 gene of herpes simplex virus type 1. Biochem Biophys Res Commun (1993) 0.79
Preferential binding of simian virus 40 T-antigen dimers to origin region I. J Virol (1989) 0.79
Modulation of the clastogenic activity of gamma-irradiation in buthionine sulphoximine-mediated glutathione depleted mammalian cells. Int J Radiat Biol (1999) 0.79
Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID). Health Technol Assess (2009) 0.79
Regulation of c-myb oncogene expression in immature and mature murine T cells. Mol Immunol (1993) 0.79
A study of energetics of cooperative interaction using a mutant lambda-repressor. Protein Eng (2000) 0.78
The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun (1995) 0.78
Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancer. Colorectal Dis (2014) 0.78
The effect of surface treatment of hydroxyapatite on the properties of a bioactive bone cement. J Mater Sci Mater Med (2004) 0.78
The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants. Int J Oncol (2001) 0.77
Genotoxic effect of raw betel-nut extract in relation to endogenous glutathione levels and its mechanism of action in mammalian cells. Mutat Res (2003) 0.77
Effect of molecular weight and concentration of poly(acrylic acid) on the formation of a polymeric calcium phosphate cement. J Mater Sci Mater Med (2003) 0.77
Placental lactogen-I variant utilizes the prolactin receptor signaling pathway. Mol Cell Endocrinol (1996) 0.77
Synthesis and evaluation of L-glutamic Acid analogs as potential anticancer agents. Indian J Pharm Sci (2010) 0.77